Tetrabenazine D6

• CAT Number: I001504
• CAS Number: 1392826-25-3
• Molecular Formula: C19H21D6NO3
• Molecular Weight: 323.46
• Purity: ≥95%
• Synonyms: Tetrabenazine D6
• Target: VMAT2 inhibitor
• Solubility: 10 mM in DMSO
• Storage: Store at RT
• IUPAC Name: (3R,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
• InChI: InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m1/s1/i3D3,4D3
• InChIKey: MKJIEFSOBYUXJB-VFJJUKLQSA-N
• SMILES: [2H]C([2H])([2H])OC1=C(C=C2[C@H]3CC(=O)[C@@H](CN3CCC2=C1)CC(C)C)OC([2H])([2H])[2H]

Tetrabenazine D6 (Cat No.:I001504), also known as SD-809, is an investigational, oral, small-molecule inhibitor of vesicular monoamine 2 transporter, or VMAT2, that is designed to regulate the levels of a specific neurotransmitter, dopamine, in the brain. Deutetrabenazine is a deuterated tetrabenazine. SD-809 is being developed for the treatment of chorea associated with Huntington’s disease, a neurodegenerative movement disorder that impacts cognition, behavior, and movements. Teva is investigating the broad potential of SD-809 for treating additional movement disorders such as tardive dyskinesia and tics associated with Tourette syndrome.